Valuation : PolyPid Ltd.

Market Cap 105M 90.14M 85.04M 77.48M 145M 10.02B 146M 1.01B 390M 5.08B 394M 385M 16.14B P/E 2026 *
-5.8x
P/E 2027 * -4.2x
Enterprise Value 105M 90.14M 85.04M 77.48M 145M 10.02B 146M 1.01B 390M 5.08B 394M 385M 16.14B EV / Sales 2026 *
6.99x
EV / Sales 2027 * 12.1x
Free-Float
82.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.77%
1 week-2.09%
Current month+0.39%
1 month+8.18%
3 months+14.41%
6 months+19.44%
Current year+18.89%
1 week 5.13
Extreme 5.13
5.56
1 month 4.54
Extreme 4.54
5.56
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.2
5 years 2.3
Extreme 2.3
257.1
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 18/08/2025
Director TitleAgeSince
Director/Board Member 84 01/04/2008
Director/Board Member 52 08/08/2022
Director/Board Member 74 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 A Free

Director

9,132 0.0896%
7/15/26 A Free

Director

9,132 0.0896%
7/15/26 A Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-2.09%+49.57%-42.65% 106M
-0.11%-3.16%+48.82%+91.49% 1,002B
-0.27%-4.34%+51.52%+65.89% 644B
+1.63%-2.00%+20.49%+71.12% 443B
-0.63%-3.09%+29.84%+34.59% 343B
+0.43%-14.61%+11.32%+27.26% 262B
+0.93%-3.19%-1.31%+8.41% 245B
-2.25%-13.88%+37.33%+47.43% 212B
-0.90%-5.06%-18.47%-57.75% 199B
-0.58%-4.24%+25.65%+90.54% 181B
Average -0.18%-4.87%+25.47%+33.63% 352.98B
Weighted average by Cap. +0.07%-4.39%+31.99%+57.11%

Financials

2026 *2027 *
Net sales 15M 12.9M 12.17M 11.09M 20.73M 1.43B 20.92M 145M 55.79M 727M 56.33M 55.1M 2.31B 8.68M 7.46M 7.04M 6.41M 11.99M 829M 12.1M 83.83M 32.26M 421M 32.58M 31.86M 1.34B
Net income -20.03M -17.22M -16.25M -14.8M -27.67M -1.91B -27.92M -194M -74.48M -971M -75.2M -73.56M -3.08B -31.55M -27.13M -25.6M -23.32M -43.6M -3.02B -43.99M -305M -117M -1.53B -118M -116M -4.86B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
10/09/26 $5.160 -0.77% 69,644
09/09/26 $5.200 -2.44% 141,577
08/09/26 $5.330 -1.11% 87,316
04/09/26 $5.390 +2.28% 73,097
03/09/26 $5.270 -0.57% 65,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.160USD
Average target price
11.75USD
Spread / Average Target
+127.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!